The NIH has agreed to help bankroll a pioneering $100 million study of Genentech's experimental Alzheimer's therapy crenezumab. Investigators will test the drug in a region of Colombia where a particular genetic mutation is known to trigger the early onset of Alzheimer's, with an eye to determining if they can stop the memory-wasting ailment before it starts. The NIH has agreed to pay for $16 million of the study, with private donors putting up $15 million more and Genentech adding the rest--about $65 million--to bankroll the effort. The announcement is part of an ambitious effort announced Tuesday to find an effective ...
A drug prescribed for Alzheimer’s disease does not ease clinically significant agitation in patients with Alzheimer’s disease, according to a new study led by the University of East Anglia (UEA).
Kelly Martin is hanging on to his executive suite at Elan for a few more months. Instead of bowing out May 1 under a longstanding exit plan, Martin has agreed to keep the title and the responsibility for the ultimate outcome of the big Phase III program for the Alzheimer's drug bapineuzumab. That data package arrives mid-year, and the changeup in the transition schedule illustrates just how big the stakes are for all involved.
Chasing one of the holy grails in the drug business, Pfizer research boss Mikael Dolsten made a case for investors and industry watchers yesterday for why his company's and Johnson & Johnson's contender in this high-profile hunt has the "best chance" to alter the progression of Alzheimer's disease, Reuters reported.
